Molecular genetic events in the development and progression of ovarian cancer in humans.
Ovarian tumor development is characterized by specific clinical and pathological features that provide an interesting model of carcinogenesis: first, the pre-invasive and even invasive lesions are difficult to detect; second, a group of cases with a known familial predilection constitute an important heredltary model of carcinogenesis; and third, the category of morphologically borderline ovarian tumors (tumors of low malignant potential) poses several unanswered questions such as: what histologic criteria should be used for their diagnosis; what is their natural history; and what is their molecular relationship to invasive tumors? Recently, molecular studies have contributed to a better understanding of the biology of these tumors, their behavior in vivo, and their response to therapy. This article summarizes the most recent molecular advances.
Chuaqui
R F
RF
Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA.
Zhuang
Z
Z
Merino
M J
MJ
D001943:Breast Neoplasms / Q000235:genetics; D002872:Chromosome Deletion; D002874:Chromosome Mapping; D004198:Disease Susceptibility; D005190:Family; D005260:Female; D016147:Genes, Tumor Suppressor; D008040:Genetic Linkage; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology*; D011956:Receptors, Cell Surface / Q000502:physiology; D017978:Receptors, Growth Factor / Q000502:physiology
D006133:Growth Substances; D011956:Receptors, Cell Surface; D017978:Receptors, Growth Factor